Lexicon reports Q1 net loss of $31.9M; PDUFA for sotagliflozin on track for May 27

LEXICON PHARMACEUTICALS, INC.

2024-Q1 EPS reported -$0.17 revenue$24,000

Q1 2023 net loss $31.9M ($0.17/share), compared to $23.5M ($0.16/share) in Q1 2022.
Cash and investments $105.9M at Mar 31, down from $138.4M at Dec 31, 2022.
NDA for heart failure drug sotagliflozin has May 27 PDUFA action date; company prepared for prompt US launch.
R&D spending fell to $12.1M; SG&A rose to $19.1M on commercial launch preparations.
LX9211 for neuropathic pain advancing; FDA feedback on late-stage development expected in Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LEXICON PHARMACEUTICALS, INC. reported the three months ended March 31, 2023 results: net income Net loss for the first quarter of 2023 was $31.9 million, or $0.17 per share, EPS $0.17 per share.

Period: the three months ended March 31, 2023
Net income: Net loss for the first quarter of 2023 was $31.9 million, or $0.17 per share
EPS: $0.17 per share
Result: reported results

Exact text from the filing

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023

View on SEC.gov

Browse all earnings releases →

LEXICON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001062822-23-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.